Under the agreement, Eris will take over the marketing and distribution rights for more than 130 products across multiple therapeutic areas owned by the generics business.
Strides Shasun and Eris Lifesciences have entered into definitive agreements for sale of Strides’ India branded generics business to Eris for an aggregate cash consideration of Rs 500 crores.